Teva Pharmaceuticals USA
Teva Pharmaceuticals USA Inc. Political Action Committee (TEVA PAC)
Lobbying: all issues, rounded to the nearest $10,000. Two filers, same 21 months. This PAC gives money raised from the company’s employees; the company itself can’t give to campaigns from its treasury.
Spend by quarter Pro
Free account See ProWhat they lobby on
MethodTeva Pharmaceuticals USA reported federal lobbying in 8 of the last 8 quarters (Q4 2024 to Q3 2026), with its own in-house lobbyists and 5 outside firms. What follows is what the filings say it lobbied on, not which way.
Issue areas ranked by quarters filedQ4 24 → Q3 26
- Copyright/Patent/Trademark8/8
- Health Issues8/8
- Medicare/Medicaid8/8
- Tariff (miscellaneous tariff bills)7/8
- Trade (domestic/foreign)7/8
Pharmacy 3 of 8 · Manufacturing 2 of 8 · Show all 7
- Pharmacy3/8
- Manufacturing2/8
Bills named in the filings 17 bills, this period
- H.R. 1843 To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.7 filings
- S.J.Res. 37 A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada.7 filings
- H.R. 6888 Trump Tariff Transparency Act4 filings
- S. 959 Tariff Transparency Act of 20254 filings
- H.R. 1613, 118th Drug Price Transparency in Medicaid Act of 20232 filings
12 more, 7 named in only one filing · Show all 17
- S. 113, 118th Prescription Pricing for the People Act of 20232 filings
- S. 142, 118th Preserve Access to Affordable Generics and Biosimilars Act2 filings
- S. 150, 118th Affordable Prescriptions for Patients Act of 20232 filings
- H.R. 5378, 118th Lower Costs, More Transparency Act Broad bill2 filings
- S. 127, 118th Pharmacy Benefit Manager Transparency Act of 2023 Broad bill2 filings
- H.R. 501, 118th Block, Report, and Suspend Suspicious Shipments Act1 filing
- S. 1067, 118th Ensuring Timely Access to Generics Act of 20231 filing
- S. 1114, 118th Expanding Access to Low-Cost Generics Act of 20231 filing
- S. 1543, 118th A bill to require regulations concerning the disclosure of direct and indirect compensation from entities providing pharmacy benefit management services or third-party administration services.1 filing
- S. 1552, 118th Coastal Fellowships Act1 filing
- S. 2305, 118th Biosimilar Red Tape Elimination Act1 filing
- S. 1339, 118th Pharmacy Benefit Manager Reform Act Broad bill1 filing
From the filings
“A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37). Tariff Transparency Act of 2025 (S.959) and Trump Tariff Transparency Act (H.R.6888).”
“Issues surrounding US Pharmaceutical supply chain. Issues surrounding the generic drug and biosimilar user free agreements. Issues surrounding the regulation of complex generic drugs. Issues related to Inflation Reduction Act. Issues related to generic drug review.”
Contacted as listed on the filings
- U.S. House
- U.S. Senate
- CMS
- EOP
- FDA
- HHS
- DHS
- DOC
- USTR
The House and Senate appear in every quarter; agencies in all 8 quarters.
Every filing since 2015 Pro
Free account See ProSource: Lobbying Disclosure Act filings (LD-2) by Teva Pharmaceuticals USA, Senate Office of Public Records. Filings are due 20 days after each quarter ends.
From FEC filings: direct gifts this PAC reported, net of refunds · How we count
Gave directly to 11 sitting members of Congress in 2025–26.
See every candidate and member Teva Pharmaceuticals USA gave to directly, how much, and how its money splits between the parties.
This part is in Pro. A free account lets you follow up to 3 people and get a weekly email about them; upgrade whenever you need more.
Create a free account See what Pro adds Log in